Guya Diletta Marconi | Biology and Life Sciences | Outstanding Scientist Award

Assoc Prof Dr. Guya Diletta Marconi | Biology and Life Sciences | Outstanding Scientist Award 

University “G. d’ Annunzio” Chieti-Pescara | Italy

Dr. Guya Diletta Marconi is a distinguished Senior Researcher in the biomedical field at the Department of Innovative Technologies in Clinical Medicine & Dentistry, University “G. d’Annunzio” of Chieti–Pescara, Italy. With a strong academic background and extensive international research exposure, she has established herself as an accomplished scientist committed to advancing translational biomedical research that bridges fundamental science and clinical application. Dr. Marconi earned her PhD in Drug Sciences in April 2016 from the University of Chieti. During her doctoral training, she spent half of her PhD period as a visiting PhD student in the United States, an experience that significantly enriched her scientific perspective and strengthened her expertise in advanced experimental methodologies. This international training fostered long-term scientific collaborations and contributed to her ability to work effectively in multicultural and interdisciplinary research environments. Her research activity is firmly rooted in highly translational basic science, with a particular focus on understanding molecular and cellular mechanisms underlying human diseases and identifying innovative therapeutic strategies. As part of a multidisciplinary research group, Dr. Marconi collaborates closely with clinicians, biologists, pharmacologists, and bioengineers to ensure that laboratory discoveries are rapidly and effectively translated into clinically relevant outcomes. Her work reflects a strong commitment to patient-oriented research, aiming to improve diagnosis, treatment, and disease management through scientific innovation. Dr. Marconi has demonstrated significant expertise in experimental design, data analysis, and the application of cutting-edge technologies in biomedical research. She actively contributes to the development of novel therapeutic approaches and diagnostic tools, integrating pharmacological, molecular, and technological perspectives.

Citation Metrics (Scopus)

3000
2000
1000
  500
  400
  300
  200
  100
    50
    30
    10
      0

Citations
2041

Documents
75

h-index
23

Citations

h-index

i10-index

View Scopus Profile

Featured Publications

Marco Miceli | Biology and Life Sciences | Best Paper Award

Dr. Marco Miceli | Biology and Life Sciences | Best Paper Award 

CEINGE-Biotecnologie Avanzate Franco Salvatore | Italy

Dr. Marco Miceli is an Italian biomedical researcher with over two decades of continuous experience in molecular biology, epigenetics, genetics, and translational biomedical research, developed within leading academic and research institutions in Italy. Born on 20 February 1973, he is currently engaged at CEINGE–Biotecnologie Avanzate “Franco Salvatore” in Naples, where since October 2022 he has been working under a fixed-term collaboration contract within the national project “TASK FORCE 2022 COVID-19”. In this role, he serves as Head of the Level III Biosafety Laboratory (BSL-3), operating under the scientific supervision of Prof. Massimo Zollo, with responsibilities encompassing high-containment laboratory management, advanced virological research, and biosafety compliance. Between 2020 and 2022, Dr. Miceli worked at the University of Naples Federico II, Department of Neurosciences, Reproductive Sciences and Odontostomatology, contributing to a CDA-funded project focused on the molecular etiology of syndromic and non-syndromic genetic hearing loss, including genotype–phenotype correlations and functional characterization of pathogenic variants. His research career has been strongly rooted at CEINGE and associated institutes, where he has held multiple research appointments since 2019, collaborating on projects spanning molecular diagnostics, functional genomics, and advanced cellular models. Earlier in his career, he served as a fixed-term researcher at the IRCCS SDN Research Institute, working on innovative projects involving amniocyte stem cells, 3D scaffolds for bone tissue engineering, and epigenetic profiling of immune cells in metabolic disorders. From 2005 onward, Dr. Miceli played a sustained role in several nationally and EU-funded research programs, including EPITRON, ATLAS, APO-SYS, and PON-SIRTT-IN, primarily under the scientific guidance of Prof. Lucia Altucci. His work during this period focused on epigenetic regulation of gene expression, chromatin immunoprecipitation (ChIP), real-time PCR, histone deacetylase complexes, apoptosis regulation, and cancer epigenetics. Dr. Miceli’s long-standing expertise spans molecular genetics, chromatin biology, lentiviral systems, stem cell models, and translational biomedical research, making him a highly experienced and reliable contributor to multidisciplinary research initiatives at the interface of basic science, clinical research, and advanced biotechnological applications.

Citation Metrics (Google Scholar)

3000
2000
1000
500
400
300
200
100
50
30
10
0

Citations
2756

Documents
39

h-index
25

Citations

Documents

h-index

View Google Scholar Profile
   View Orcid Profile

Featured Publications

Shohei Katsuya | Biology and Life Sciences | Excellence in Research Award

Mr. Shohei Katsuya | Biology and Life Sciences | Excellence in Research Award

OSAKA GAS Co., Ltd. | Japan

Mr. Shohei Katsuya is a dedicated Researcher at the Advanced Technology Research Institute of Osaka Gas Co., Ltd., where he has been contributing to cutting-edge scientific advancements since April 2021. He holds a Master of Agriculture degree from Kyoto University, earned in March 2021, and has since developed a strong research focus on the physiological functions of beta-hydroxybutyrate (BHB). His work revolves around understanding how BHB influences metabolic regulation, ketone body pathways, and physiological responses related to obesity and visceral fat accumulation. As metabolic disorders continue to rise globally, his research addresses critical scientific questions with direct implications for human health, nutrition, and disease prevention. Shohei has played an active role in developing nutritional strategies aimed at improving metabolic outcomes, collaborating with academic institutions, and supporting multidisciplinary projects that advance metabolic health science. Between 2023 and 2025, Shohei has authored five peer-reviewed publications in reputable international journals, including Obesities, Journal of Nutritional Science and Vitaminology, Bioscience, Biotechnology, and Biochemistry, and Nutrition. These publications collectively reflect his commitment to scientific rigor and his growing influence in the fields of nutritional science and metabolic physiology. His research output has received 18 citations to date, according to Scopus metrics (as of November 2025), and his current h-index of 2 indicates early yet solid scholarly impact within a short timeframe. His contributions provide valuable insights into ketone-body-driven metabolic pathways, opening possibilities for new therapeutic and dietary approaches. Shohei’s research activities align strongly with the mission of advancing evidence-based nutrition and metabolic science, demonstrating originality, societal relevance, and a high level of research integrity. His projects emphasize translational potential—particularly in dietary interventions for visceral fat reduction—and reflect an understanding of both biochemical mechanisms and practical applications for health improvement. Through continuous collaboration with academic partners, Shohei has strengthened his ability to transform scientific concepts into meaningful innovations that address modern health challenges. His commitment to excellence, ethical research practice, and impactful scientific contribution make him a strong candidate for the Excellence in Research Award. Shohei declares that all information provided in this application is accurate and authentic to the best of his knowledge, and he remains fully committed to upholding the values and standards of the International Research Awards.

Profiles: Scopus | Orcid

Featured Publications

Aisyah, R., Katsuya, S., Miyata, K., Chen, Z., Horii, M., Kudo, A., Kumrungsee, T., Tsubota, J., & Yanaka, N. (2025). β-hydroxybutyrate attenuates diabetic renal and muscular pathologies in a streptozotocin-induced diabetic model. Nutrition, 112792. https://doi.org/10.1016/j.nut.2025.112792

Katsuya, S., Kawata, Y., Kawamura, Y., Kawamura, J., & Tsubota, J. (2025). Effect of d-β-hydroxybutyrate on sleep quality in healthy participants: A randomized, double-blind, placebo-controlled study. Bioscience, Biotechnology, and Biochemistry. https://doi.org/10.1093/bbb/zbaf017

Katsuya, S., Kawata, Y., Sugimoto, M., Nishimura, T., & Tsubota, J. (2024). Determination of the safety of Halomonas sp. KM-1-derived d-β-hydroxybutyric acid and its fermentation-derived impurities in mice and Japanese adults. Bioscience, Biotechnology, and Biochemistry. https://doi.org/10.1093/bbb/zbae088

Ip, C.-H., Higuchi, H., Wu, C.-Y., Okuda, T., Katsuya, S., Ogawa, J., & Ando, A. (2024). Production of docosahexaenoic acid by a novel isolated Aurantiochytrium sp. 6-2 using fermented defatted soybean as a nitrogen source for sustainable fish feed development. Bioscience, Biotechnology, and Biochemistry. https://doi.org/10.1093/bbb/zbae035

Katsuya, S., Kawata, Y., Goto, T., & Tsubota, J. (2023). Daily intake of D-β-hydroxybutyric acid (D-BHB) reduces body fat in Japanese adult participants: A randomized, double-blind, placebo-controlled study. Journal of Nutritional Science and Vitaminology, 69(2), 121–129. https://doi.org/10.3177/jnsv.69.121

Zu-Chian Chiang | Biochemistry | Best Researcher Award | 13347

Dr. Zu-Chian Chiang | Biochemistry | Best Researcher Award 

Dr. Zu-Chian Chiang, Fujian Normal University, China

Dr. Zu-Chian Chiang is a postdoctoral fellow at the Biomedical Research Center of Southern China, Fujian Normal University, China, with a rich background in materials and chemical engineering. His research contributions span antibody-drug conjugates (ADCs), functional peptide synthesis, biomaterials for regenerative medicine, and aptamer-based cancer therapy. His work has geographic impact across Taiwan and Mainland China, contributing to translational medicine and oncology through collaborative efforts with prestigious institutions like Academia Sinica and National Taiwan University. His applied research in ADCs and biomaterial scaffolds directly supports cancer treatment innovations. Notable projects include the development of CD47-targeting ADCs for non-small cell lung cancer, and thalidomide-PD1 combinations for enhanced immunotherapy. His publications in Frontiers in Oncology, PLOS ONE, and Current Pharmaceutical Biotechnology highlight his influence in drug delivery and cancer therapeutics. In the vector control domain, his scaffold research contributes to potential localized drug delivery systems. Dr. Chiang has received awards such as the Science and Technology Commissioner honor from Quanzhou and the Biotech Elite Training Award. His achievements exemplify impactful biomedical research with real-world therapeutic implications.

Profile

Scopus

🌱 Early Academic Pursuits

Dr. Zu-Chian Chiang embarked on his scientific journey with a passion for chemistry and materials science. He earned his Master’s Degree in Chemistry from Tunghai University, Taiwan (2005–2007), under the guidance of Prof. Feng-Di Lung. Building on this solid foundation, he pursued his Ph.D. in Materials and Chemical Engineering at National United University, Taiwan (2008–2014). During his doctoral studies, he was mentored by Prof. An-Chong Chao and co-advised by Dr. Guo-Chung Dong, focusing on biomaterials and nanomedicine.

Even as a student, Dr. Chiang demonstrated exceptional academic capabilities, earning scholarships and recognition for his innovative research. His academic training laid the groundwork for his future contributions in biomedical engineering and cancer therapeutics.

🧪 Professional Endeavors

Dr. Chiang has held several prestigious postdoctoral positions. His professional journey reflects a commitment to interdisciplinary collaboration and translational research:

  • Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University (2019–Present), working under Prof. Qi Chen.

  • Postdoctoral Fellow at the Institute of Biological Chemistry, Academia Sinica, Taiwan (2016–2019), contributing to the Taiwan Protein Project (TPP) and the Technical Support Platform Spindle Project (TSPA).

  • Postdoctoral Fellow at the Clinical Trial Center, National Taiwan University Hospital (2015–2016), supported by Taiwan’s prestigious Biotech Elite Training Program.

Throughout these roles, Dr. Chiang has engaged in cutting-edge biomedical research with direct implications for drug development and clinical applications.

🔬 Contributions and Research Focus

Dr. Chiang’s research centers on innovative therapeutic materials and drug delivery systems, particularly in cancer therapy. His core interests include:

  • Antibody-Drug Conjugates (ADCs): Targeted cancer therapies such as HER2-positive and CD47-specific ADCs.

  • Functional Peptide Synthesis for bone tissue engineering and cancer inhibition.

  • Bio-Micro-Macro Molecular Materials for regenerative medicine.

  • Aptamer Development as modulators in therapeutic settings.

Notable publications include research on CD47-targeting ADCs (Frontiers in Oncology, 2022) and HER2-positive ADCs (PLOS ONE, 2020). His work on dexamethasone-immobilized chitosan scaffolds and chitosan-caffeic acid hybrids also provides valuable insights into localized drug delivery and tissue engineering.

🏆 Accolades and Recognition

Dr. Chiang’s dedication has been acknowledged through numerous awards:

  • 🥇 Science and Technology Commissioner, Quanzhou, Fujian Province (2020)

  • 🥇 Biotech Elite Training Award, National Taiwan University & Ministry of Science and Technology (2016)

  • 🥇 Chung Hwa Rotary Doctoral Program Award, Taiwan (2012)

  • 🥇 Outstanding Doctoral Scholarship, National United University (2010)

  • 🥇 Master’s Program Scholarship, Hunan Fellow Association of Taiwan (2007)

  • 🥇 Rotary Leadership Award, Miaoli Southeastern Xindong Satellite Rotary Club (2017)

These accolades affirm his position as a respected figure in the fields of biomedical chemistry and translational medicine.

🌍 Impact and Influence

Dr. Chiang’s work has made a geographic impact spanning Taiwan and Mainland China. His collaborative research in academia and clinical centers bridges the gap between laboratory research and therapeutic application. He actively contributes as a peer reviewer for the International Journal of Biological Macromolecules, influencing scientific standards and publication quality globally.

He is also engaged in community service through leadership in Rotary International, fostering science-driven community development and education.

🌟 Legacy and Future Contributions

Dr. Chiang’s legacy is being built on the foundation of scientific excellence, mentorship, and translational impact. His research not only pushes the boundaries of biomedical engineering but also aims to enhance the effectiveness of cancer treatments in clinical practice. With a commitment to developing next-generation targeted therapies and biomaterial scaffolds, Dr. Chiang is poised to shape the future of personalized medicine and regenerative technologies.

Looking ahead, he aims to establish interdisciplinary collaborations and contribute to global health initiatives, making life-saving therapies more effective and accessible.

Publication Top Notes

Development of Novel CD47-Specifific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo. 

Author: Z.C., Chiang, Zu Chian, S., Fang, Shubin, Y., Shen, Yangkun, J., Lin, Jizhen, Q., Chen, Qi

Journal: Frontiers in Oncology,

Year: 2022

Preparation and characterization of dexamethasone-immobilized chitosan scaffold

Author: Z.C., Chiang, Zu Chian, S., Yu, Shuhuei, A., Chao, Anchong, G.C., Dong, Guo Chung

Journal: Journal of Bioscience and Bioengineering, 

Year: 2012